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Abstract Acne vulgaris affects up to 80% of people 11 to
30 years of age, and scarring can occur for up to 95% of
these patients. Scarring may be pitted or hypertrophic in
nature, although in most cases it is atrophic. Atrophic acne
scarring follows dermal collagen and fat loss after mod-
erate to severe acne infection. Injectable poly-L-acid
(PLLA) is a biocompatible, biodegradable, synthetic
polymer device that is hypothesized to enhance dermal
volume via the endogenous production of ﬁbroblasts and,
subsequently, collagen. The gradual improvements in
cutaneous volume observed after treatment with injectable
PLLA have been noted to last up to 2 years. The case
studies presented describe the use of injectable PLLA to
correct dermal fat loss in macular atrophic acne scarring of
the cheeks. Two female patients underwent three treatment
sessions with injectable PLLA over a 12-week period. At
each treatment session, the reconstituted product was
injected into the deep dermis under the depressed portion
of the scar. Both patients were extremely pleased with their
results at, respectively, 1- and 4-year follow-up evalua-
tions. Patients experienced minimal swelling and redness
after injection and no product-related adverse events such
as papule and/or nodule formation. The author believes
these data suggest that injectable PLLA is a good treatment
option for the correction of macular atropic scarring with
thin dermis (off-label use), particularly compared with
other injectable ﬁllers currently used for this indication that
have shorter durations of effect.
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Scarring
Acne vulgaris is the most common of all skin diseases, and
although it can occur at any age, it affects up to 80% of
people ranging in age from 11 to 30 years [12]. Further-
more, infectious acne leads to sequelae that include scarring
and various forms of contour abnormalities [3]. In fact,
scarring can occur in up to 95% of acne patients [14]. The
scarring may be pitted ‘‘atrophic,’’ macular ‘‘atrophic,’’ or
hypertrophic in nature [6, 8, 10], and it has a negative
impact on patient self-esteem and quality of life [5, 15].
To correct the signs of acne scarring, a number of dif-
ferent treatments have been used such as dermabrasion,
laser resurfacing, skin grafting, punch excisions, chemical
peels, subcision, and injectable agents. However, because
scarring can vary considerably in depth and type, different
techniques often are applied simultaneously or in series,
according to the type of scar, to achieve an adequate
treatment effect [1, 3, 9, 22].
This article focuses on the treatment of macular atrophic
scars, such as boxcar scars. Macular atrophic scars are
broad in nature, create less stark shadows, and are easier to
conceal with makeup than small and deep ice-pick scars.
The concept of using injectable agents such as collagen,
hyaluronic acid, and silicone to ﬁll this type of scarring has
long been established [2, 11, 13]. In the two reported case
studies, injectable poly-L-acid (PLLA; Sculptra; Dermik
Laboratories, a division of Sanoﬁ-Aventis U.S. LLC,
Bridgewater, NJ, USA) was used to correct dermal fat loss
associated with macular atrophic scarring after severe
chronic acne.
Injectable PLLA is a biocompatible, biodegradable,
synthetic polymer widely used throughout Europe, the
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correction of lipoatrophy signs in people with human
immunodeﬁciency virus (HIV) [16, 17, 21]. Injectable
PLLA also is approved in Europe, Brazil, Australia, and
Canada for the cosmetic correction of facial volume
defects. It currently is under review by the Food and Drug
Administration in the United States for volume restoration
or correction of facial wrinkles and folds such as nasolabial
lines or folds.
After injection, PLLA is thought to elicit the endoge-
nous production of ﬁbroblasts and, subsequently, collagen,
thereby enhancing tissue volume gradually over time [7,
19]. Signiﬁcant increases in dermal volume have been
observed after administration of injectable PLLA, with
results observed to last up to 2 years and potentially longer
in certain instances [4, 16–18, 22].
Although injectable PLLA is not appropriate for treating
all varieties of acne scarring, it can be used effectively to
replace lost dermal volume in depressed scars (i.e., those
caused by loss of lower dermis or subcutaneous fat), such
as macular atrophic scars [3]. Recently, injectable PLLA
has been used successfully to correct this type of scarring
after either severe acne or varicella (chicken-pox) virus
infection, demonstrating signiﬁcant reductions in acne scar
size and severity [3].
The author, with considerable experience using inject-
able PLLA for the effective correction of depressed facial
acne scarring, presents two case studies describing such
treatment. The use of injectable PLLA for active acne,
hypotrophic, keloid, or ice-pick scarring is not advocated.
It should be noted that injectable PLLA is not currently
indicated for the correction of acne scaring in the United
States, and that this article describes off-label use of the
agent for this purpose. Additionally, the reconstitution and
administration practices detailed may not reﬂect the man-




Injectable PLLA was used to treat two women, ages 21
(Fig. 1) and 45 years (Fig. 2), with dermal fat atrophy
caused by chronic and severe facial acne of the cheeks.
Both patients, in good health with no comorbid diseases or
infections, signed consent forms before treatment.
The 45-year-old patient received one carbon dioxide
(CO2) laser peel 6 months before her PLLA injections.
Pretreatment consultation included the rationale for using
injectable PLLA, as opposed to collagen, hyaluronic acid,
or silicone ﬁllers. The considerable volume enhancement
elicited with injectable PLLA was described, as well as the
potential longevity of the results.
The patients also were advised that after injection with
PLLA, increases in dermal volume would occur gradually
over time due to the hypothesized mode of operation. A few
weekswouldberequireduntiltheﬁrstsignsofimprovement.
It was explained to the patients that after PLLA injection,
they might experience transient injection-related adverse
effects such as swelling, redness, and possibly bruising, and
that these effects would most likely resolve spontaneously.
Treatment
Each patient underwent three treatment sessions with
injectable PLLA spaced 6 weeks apart. For injection at
every treatment, the product was reconstituted with 5 ml of
sterile water and allowed to stand for 24 h before injection.
All areas on the cheeks to be treated were ﬁrst cleansed
with alcohol and then injected with anesthetic (1% lido-
caine epinephrine administered with a 30-gauge needle).
At each treatment session, injectable PLLA was
administered into the deep dermis with a 23-gauge 2-in.
needle. In the author’s opinion, a 23-gauge needle results in
Fig. 1 Case study 1.
Photographs before (a) and
1 year after (b) the ﬁnal
treatment of a 21-year-old
patient who underwent three
injectable poly-L-lactic acid
treatment (dermal lipoatrophy)
sessions for facial ‘‘scarring’’
caused by chronic acne
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mended 26-gauge needle [20] and therefore can afford
more controlled injection of material. Furthermore, as the
anesthetic is administered by the author before treatment,
the increased needle size does not result in increased
patient discomfort.
With the needle positioned under the depressed portion
of the scar, PLLA was placed at the dermal/subcutaneous
tissue junction using a layering technique. A small amount
of material (1 ml), dispersed throughout the skin, was
injected under low pressure with this method, using an
active motion of the needle to avoid ‘‘lakeing’’ of inject-
able PLLA beneath the skin. The material was deposited
under the dermis because the epidermis and dermis of the
acne scar tissue was very thin.
Injections to speciﬁc scars were complete when the level
of the treated area was raised to that of the surrounding
skin. Altogether, 2 ml of injectable PLLA per cheek was
deposited under the surface of the dermis for a total volume
of 4 ml per treatment session.
No massage was performed after injection for acne
scaring, and patients were discouraged from performing
this action. It is important to note that during correction of
age- or HIV-associated lipoatrophy with injectable PLLA,
massage is regularly used to ensure an even distribution of
the product. However, with the layering procedure used for
these patients, the author believes that adequate and even
distribution of the material can be achieved through the use
of correct injection technique.
Results
The patients experienced minimal swelling and redness for
24 to 48 h after injection. No product-related adverse
events, such as papule or nodule formation, were noted at
the 3-year follow-up evaluation for the 21-year-old or at
the 6-year follow-up evaluation for the 45-year-old. After
1 year of treatment with injectable PLLA for the 21-year-
old (Fig. 1b) and 4 years of treatment for the 45-year-old
(Fig. 2b), the author determined the results to be excellent,
as assessed using photographs and physical examination.
Furthermore, each patient was extremely pleased with the
results, and speciﬁcally, the improvement in the contour
and color of the treated areas. Fewer shadows in the skin
were apparent. The case studies suggest that injectable
PLLA is a good treatment option for the correction of
dermal fat atrophy after severe acne.
Discussion
Theseverityandmorphologyofacnescarringoftenislinked
to the intensity of the disease, and in most cases scarring is
atrophic [14]. Like all scars, acne scars are visible due to
their color and the shadows they create in the skin. The
morphology of an atrophic scar is inﬂuenced by the loss of
collagen and sometimes the loss of subcutaneous fat (lipo-
atrophy) that results from acne infection. After mild acne,
soft papular and rolling (gently undulating) scars can
Fig. 2 Case study 2.
Photographs before (a) and
4 years after (b) the ﬁnal
treatment of a 45-year-old
patient who underwent three
poly-L-lactic acid treatment
(dermal lipoatrophy) sessions
for facial ‘‘scarring’’ caused by
chronic acne
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papular and rolling scars are more prominent. Boxcar scars
that are polygonal and terminate in the shallow-to-mid
dermis also may develop with moderate acne. Severe acne
can lead to gross atrophy, dystrophic scars, signiﬁcant
hypertrophy,and/orkeloids.Ice-pickscars,whichareround,
deep, pitted, and tapered into the dermis, also can appear,
along with deep boxcar scars that terminate in the reticular
dermis. The destruction and dissolution of the lower dermis
and the lipoatrophy that characterizes these atrophic scars
usually occur at the time of chronic or active disease.
Previous methods for treating acne scarring have
involved applying a number of treatments. For example,
Whang and Lee (1999) developed an effective three-step
therapeutic approach to treat various types of acne scaring
[23]. Initially, focal chemical peeling (with 50% trichlo-
roacetic acid) was undertaken to form new granulation
tissue [23]. This was followed by CO2 laserbrasion (for
pitted scars), excision (for large linear and isolated scars in
skin creases), or punch grafting/elevations (for ice-pick
scars) [23]. Dermabrasion used to be the ﬁnal step for
resurfacing any remaining irregularities [23].
The reported cases demonstrate the use of a single
injectable agent for successful treatment of fat atrophy
secondary to severe acne. Injectable PLLA is a biocom-
patible, biodegradable, synthetic polymer hypothesized to
elicit the endogenous production of ﬁbroblasts and, subse-
quently, collagen. Currently, little information on the use of
injectable PLLA for the treatment of macular dermal atro-
phy after severe acne is available. However, the reported
case studies indicate that injectable PLLA is a good treat-
ment option for the correction of dermal fat atrophy after
severe acne. The author believes that correction for this type
of scarring with injectable PLLA is elicited by ﬁlling of the
scar as collagen is replaced, and that this volume
enhancement may be more substantial and durable than that
resulting from the use of other dermal injectable agents.
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